Trial Profile

A Trial to Evaluate the Safety and Immunogenicity of Monovalent H5N1 Vaccine in Adults ≥18 Yrs of Age

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza A virus vaccine-H5N1 (Primary) ; AS03A; AS03B
Indications Influenza virus infections
Focus Adverse reactions; Pharmacodynamics
Sponsors GlaxoSmithKline; GSK

Most Recent Events

23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
21 Oct 2011 Secondary endpoint 'Seroconversion-rate' has been met (3063141).
21 Oct 2011 Primary endpoint 'Geometric-mean-antibody-titre' has been met (3063141).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com